Preoperative Plasma Levels of Transforming Growth Factor Beta(1) Strongly Predict Clinical Outcome in Patients with Bladder Carcinoma
Overview
Affiliations
Background: Elevated local and circulating levels of transforming growth factor (TGF)-beta(1) have been associated with cancer invasion, progression, and metastasis. The authors tested the hypothesis that preoperative plasma TGF-beta(1) levels would independently predict cancer stage and prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder.
Methods: The study group consisted of 51 patients who underwent radical cystectomy for muscle-invasive or intravesical immuno- and/or chemotherapy refractory Tis, Ta, or T1 TCC (median follow-up, 45.7 months). Preoperative plasma levels of TGF-beta(1) were measured and correlated with pathologic features and clinical outcome. Transforming growth factor-beta(1) levels also were measured in 44 healthy men without any cancer.
Results: The mean preoperative plasma TGF-beta(1) level in patients who eventually developed metastases to distant (11.9 +/- 0.9 ng/mL) or regional (9.6 +/- 2.4 ng/mL) lymph nodes was significantly higher than that in patients with nonmetastatic muscle-invasive TCC (5.4 +/- 1.1 ng/mL), which, in turn, was significantly higher than that in patients with nonmetastatic Tis, Ta, or T1 TCC (4.5 +/- 1.2 ng/mL) and healthy subjects (4.5 +/- 1.2 ng/mL; P < 0.001). Preoperative plasma TGF-beta(1) level was an independent predictor of lymphovascular invasion (P = 0.002), metastases to lymph nodes (P = 0.030), disease recurrence (P = 0.009), and disease specific survival (P = 0.015). In a subgroup of patients with muscle-invasive TCC, TGF-beta(1) level was associated with disease recurrence (P = 0.005) and death from bladder carcinoma (P = 0.001).
Conclusions: The authors confirm that plasma TGF-beta(1) levels are elevated in patients with muscle-invasive TCC before cystectomy. Transforming growth factor-beta(1) levels are highest in patients with bladder carcinoma metastatic to lymph nodes and are a strong independent predictor of disease recurrence and disease specific mortality.
Association of WHSC1/NSD2 and T-cell infiltration with prostate cancer metastasis and prognosis.
Li Q, Zhu J, Zhang Y, Pan Y, Li Z, Wang M Sci Rep. 2023; 13(1):21629.
PMID: 38062230 PMC: 10703870. DOI: 10.1038/s41598-023-48906-8.
Martins-Lima C, Chianese U, Benedetti R, Altucci L, Jeronimo C, Correia M Front Mol Biosci. 2023; 9:1070383.
PMID: 36699696 PMC: 9868260. DOI: 10.3389/fmolb.2022.1070383.
Exploiting Canonical TGFβ Signaling in Cancer Treatment.
Liu Q, Chen G, Moore J, Guix I, Placantonakis D, Barcellos-Hoff M Mol Cancer Ther. 2021; 21(1):16-24.
PMID: 34670783 PMC: 8742762. DOI: 10.1158/1535-7163.MCT-20-0891.
Kerr B, Harris K, Shi L, Willey J, Soto-Pantoja D, Byzova T Am J Clin Exp Urol. 2021; 9(1):18-31.
PMID: 33816691 PMC: 8012834.
Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K World J Urol. 2021; 39(9):3345-3352.
PMID: 33496841 PMC: 8510920. DOI: 10.1007/s00345-020-03586-1.